Premium
FEASIBILITY AND BENEFIT OF MOLECULARLY‐INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Author(s) -
Michot J.,
CamaraClayette V.,
Detolle A.,
Chahine C.,
Lazarovici J.,
Danu A.,
Bosq J.,
Ghez D.,
RomanoMartin P.,
Dartigues P.,
ArfiRouche J.,
Bahleda R.,
Rahali W.,
Varga A.,
Baldini C.,
Tselikas L.,
Paume C.,
Lecourt H.,
Cotteret S.,
Vergé V.,
Soria J.,
Massard C.,
Ribrag V.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.142_2630
Subject(s) - medicine , oncology , clinical trial , progression free survival , refractory (planetary science) , salvage therapy , chemotherapy , biology , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom